Our ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of our innovative peptide technology.
Our focus is on applying our peptide technology across a wide range of indications through independent and partnered development pathways.
We’re looking for passionate, innovative individuals who can help us to deliver our technology to the people who need it most, and we’ve fostered a unique working culture to support this mission.
World-renowned Neuromuscular Disease and Oligonucleotide experts Matthew Wood, M.D., Ph.D., Art Krieg, M.D., Elizabeth McNally, M.D., Ph.D., Charles Thornton, M.D., Jonathon Watts, Ph.D., and Brenda Wong, M.D., to join PepGen’s Scientific Advisory Board Boston, Mass. and Oxford, UK (February 26, 2021) – PepGen, an emerging biotechnology company focused on transforming…
Seasoned biotech executive with deep experience and proven track record in successfully leading rare disease companies through rapid growth and development Boston, Mass. and Oxford, UK (February 4th, 2021) – PepGen, a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the enhanced…
RA Capital Management leads $45M Series A financing for PepGen’s next-generation oligonucleotide platform targeting Duchenne muscular dystrophy and other rare neuromuscular and cardiac diseases. PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also…
